ArticleBMC infectious diseases2025
Epidemiological investigation and clinical characteristics study of orthopedic infections caused by Aeromonas in the southeast coastal region from 2018 to 2024.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveTo investigate the clinical and epidemiological characteristics of trauma-related orthopedic Aeromonas infections and analyze prognostic risk factors to guide early diagnosis and inform clinical management.
methodsThis retrospective study analyzed 111 patients with traumatic Aeromonas infection from May 2018 to May 2024. Data on demographics, injury characteristics, laboratory parameters, treatment details, and outcomes were collected. Independent predictors of unfavorable prognosis were identified through univariate and multivariate logistic regression, with model performance evaluated via likelihood ratio test, ROC analysis, Hosmer-Lemeshow test, and confusion matrix.
resultsA total of 111 patients with trauma-related Aeromonas infection were collected, with an average age of 49.9 ± 14.3 years. The average length of hospital stay was 36.2 ± 21.1 days, and the average number of surgeries was 2.7 ± 1.6. The outcomes included debridement in 51(45.95%) cases, skin grafting in 17(15.32%) cases, flaps in 27(24.32%) cases, amputation in 14(12.61%) cases, and death in 2(1.80%) cases. The drug sensitivity test results showed that Aeromonas extracted from the wound secretions were resistant to ampicillin and amoxicillin and were sensitive to amikacin, levofloxacin and cefepime. Our research has listed three predictive indicators significantly associated with unfavourable prognosis, mainly including body mass index (BMI), skin defect and perioperative blood transfusion.
conclusionThis study outlines the clinical profile of traumatic Aeromonas infection, which predominantly affects middle-aged individuals and is associated with extended hospital stays, frequent surgical interventions, and significant rates of adverse outcomes, including amputation (12.61%) and mortality (1.80%). Multivariate analysis identified BMI > 23.7 kg/m², skin defects, and perioperative blood transfusion as independent predictors of poor prognosis. For high-risk trauma patients with these factors, our model recommends prophylactic use of third-generation cephalosporins (e.g., ceftazidime), aminoglycosides (e.g., amikacin), or combination therapy in place of first-line cephalosporins. Vigilant perioperative monitoring for invasive infections is crucial, especially in immunocompromised patients. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.